

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

681815

In re Patent Application of

Atty Dkt. 121-160

C# M#

PARIKH et al

Group Art Unit: 1615


Serial No. 09/281,430

Examiner: Ware, T.

Filed: March 30, 1999

Date: October 10, 2000

Title: ANTICANCER COMPOSITIONS

Assistant Commissioner for Patents
Washington, DC 20231

RECEIVED

OCT 16 2000

TECH CENTER 1600/2900

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment **26** minus highest number
previously paid for **26** (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment **6** minus highest number
previously paid for **6** (at least 3) = 0 x \$ 80.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$270.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$390.00/2 months; \$890.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$710.00) \$ 0.00
☐ Please enter the previously unentered, filed
☐ Submission attached

☐ Request for Continued Examination pursuant to 37 C.F.R. § 1.114 (\$710.00) \$ 0.00
☐ Please enter the previously unentered, filed

or ☐ Required submission attached

Subtotal \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract
☐ Statement filed herewith -\$ 0.00

Rule 56 Information Disclosure Statement Filing Fee (\$240.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: 0.00

TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
ARC:pfc

NIXON & VANDERHYE P.C.
By Atty: Arthur R. Crawford, Reg. No. 25,327

Signature: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

PARIKH et al

Serial No. 09/281,430

Filed: March 30, 1999

For: ANTICANCER COMPOSITIONS



Atty. Ref.: 121-160

Group: 1615

Examiner: Ware, T.

7/10
Atkinson
10/24/00

* * * * *

October 10, 2000

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

AMENDMENT

Responsive to the Official Action dated July 17, 2000, please amend the
above-identified application as follows:

IN THE CLAIMS

A

1. (Amended) A pharmaceutical composition comprising an anticancer drug as
active ingredient dissolved in a non-aqueous carrier system [comprising] consisting
essentially of at least one hydrophobic component, a hydrophilic component and at least
one surfactant, wherein the hydrophobic component is selected from triglycerides,
diglycerides, monoglycerides, free fatty acids, and fatty acid esters[and derivatives
thereof], individually or in combination and wherein the hydrophilic component is a

B